The World Health Organization (WHO) has backed clinical trials for two new Ebola vaccines designed specifically for the Bundibugyo virus, the rare strain causing the largest Ebola outbreak in the Democratic Republic of the Congo (DRC)’s history.
WHO chief Tedros Adhanom Ghebreyesus said expert groups had recommended adding the two candidates to the ongoing "Tumaini" multi-vaccine trial in the eastern city of Bunia. The trial had previously been using the Ervebo vaccine, which is approved for the Zaire strain but not for Bundibugyo.
The outbreak, which began in the DRC in May, has infected more than 10,000 people and killed more than 5,300, with a fatality rate above 50%. Cases have also been reported in Kenya, Nigeria and Uganda, though the DRC remains the epicentre.
The two candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and mRNA-1469, developed by Moderna. The trial is led by the DRC's National Institute for Biomedical Research, with support from WHO and other international partners. Results are expected in early 2027.
"Vaccines are powerful tools, but they are not substitutes for the proven measures that can save lives now: early care, contact tracing, isolation, safe and dignified burials and trusted engagement with communities," Tedros told reporters in Geneva.
Tedros also condemned travel restrictions imposed by some countries, including Ghana and the United States, on travellers arriving from the DRC, urging they be lifted. "Such restrictions punish countries for doing the right thing, create disincentives for transparency, and harm the response," he said, a position shared by the Africa Centres for Disease Control and Prevention.
Meanwhile, a British healthcare worker infected with Ebola is being evacuated from the DRC to the United Kingdom for specialist treatment. The UK government said in a statement that the patient is in a stable condition and the risk to the UK public remains low.
Analysis
Why This Matters
- The Bundibugyo virus has a fatality rate above 50% and no approved vaccine or treatment, making a targeted vaccine a critical step in controlling the outbreak.
- The outbreak is the fastest-growing and most widespread Ebola epidemic on record, demonstrating the urgent need for new public health tools.
- The inclusion of an mRNA candidate (Moderna) mirrors the platform used successfully for COVID-19, potentially accelerating future vaccine development for other pathogens.
Background
The current outbreak, caused by the Bundibugyo species of the Ebola virus, began in the DRC in May 2026. Unlike the more common Zaire strain, no licensed vaccine exists for Bundibugyo. The WHO and DRC launched the Tumaini multi-vaccine trial in October, initially testing the Ervebo vaccine for cross-protection. The two new candidates are the first designed specifically for Bundibugyo to be tested during an active outbreak.
Key Perspectives
- WHO Director-General Tedros Adhanom Ghebreyesus: said the vaccine candidates could become a powerful new tool but stressed they are not a substitute for proven public health measures. He condemned travel restrictions, arguing they punish countries for transparency.
- Africa Centres for Disease Control and Prevention (Africa CDC): has consistently opposed travel restrictions, stating they should not be used as a primary public health tool during outbreaks.
- Countries imposing travel restrictions (e.g., Ghana, United States): have introduced restrictions on travellers arriving from the DRC, a move the WHO has recommended against.
What to Watch
- Results from the vaccine trials are expected in early 2027.
- The spread of cases to neighbouring countries and the effectiveness of cross-border preparedness.
- The outcome of the British healthcare worker evacuated to the UK for specialist treatment.
Checked
12 claims in this story checked against 4 sources: 11 supported.
Show each claim
- SupportedTedros said vaccines are powerful tools but are not substitutes for early care, contact tracing, isolation, safe and dignified burials, and trusted community engagement.Al Jazeera – Breaking News, World News and Video from Al Jazeera: ““Vaccines are powerful tools, but they are not substitutes for the proven measures that can save lives now: early care, contact tracing, isolation, safe and dignified burials and trusted engagement with communities,””
- SupportedTedros said travel restrictions punish countries for doing the right thing, discourage transparency and harm the response.Al Jazeera – Breaking News, World News and Video from Al Jazeera: ““Such restrictions punish countries for doing the right thing, create disincentives for transparency, and harm the response,” said Tedros.”
- SupportedWHO has backed trials for two new vaccines against the Ebola outbreak.Euronews: “The World Health Organization (WHO) has backed clinical trials for two new Ebola vaccine candidates”
- SupportedThe two candidates were recommended for a trial because they were developed specifically for Bundibugyo virus.Euronews: ““Today WHO expert groups are recommending adding two vaccine candidates to the trial that had been developed specifically for the Bundibugyo virus,””
- SupportedThe outbreak death toll exceeds 5,300.Al Jazeera – Breaking News, World News and Video from Al Jazeera: “On Monday, WHO expert groups recommended adding two vaccine trials designed to fight the Bundibugyo strain, which has killed more than 5,300 people, most in the DRC, since May.”
- SupportedThe outbreak is caused by the rare Bundibugyo virus and is the largest Ebola outbreak in the DRC’s history.UN News - Global perspective Human stories: “The DRC has been battling a deadly outbreak of Ebola disease caused by the rare Bundibugyo virus species for nearly six months and it has become the largest in the country’s history.”
- Partly supportedTedros said expert groups recommended adding the candidates to the ongoing Tumaini multi-vaccine trial in Bunia.Euronews: ““Today WHO expert groups are recommending adding two vaccine candidates to the trial that had been developed specifically for the Bundibugyo virus,” WHO chief Tedros Adhanom Ghebreyesus told reporters during a press conference in Geneva on Wednesday.”
- SupportedThe trial had been using Ervebo, which is approved for the Zaire strain but not designed for Bundibugyo.Al Jazeera – Breaking News, World News and Video from Al Jazeera: “Tedros said a trial that began last month used the Ervebo vaccine, which was approved for the Zaire strain of the Ebola virus but is not designed for Bundibugyo.”
- SupportedThe outbreak has infected more than 10,000 people.Euronews: “The outbreak, which began in the DRC in May, has infected more than 10,000 people, with a fatality rate of over 50%”
- SupportedThe outbreak’s fatality rate is above 50%.RTÉ News: “A total of 10,444 cases have been confirmed, with a fatality rate of more than 50%, it added.”
- SupportedCases have been reported in Kenya, Nigeria and Uganda, while the DRC remains the epicentre.Euronews: “Cases have also been reported in Kenya, Nigeria and Uganda, although the DRC remains the epicentre”
- SupportedA British healthcare worker infected with Ebola is being evacuated from the DRC to the UK; the government said the patient is stable and the risk to the UK public is low.Al Jazeera – Breaking News, World News and Video from Al Jazeera: “Meanwhile, a British healthcare worker infected with Ebola is being evacuated from the DRC to the United Kingdom for specialist treatment, a UK government spokesperson said. In a statement, the government said the patient is in a stable condition”